Clinical Trial News
As we begin a new year, the outlook for advancements in the treatment of MPNs is promising. Below we have highlighted recent news, including follow-up from the the annual ASH meeting, and updates on potential new treatments in the pipeline:

Bomedemstat Fast Tracked for ET- Imago BioSciences will begin the study of their LSD1 inhibitor bomedemstat (IMG-7289) for the treatment of essential thrombocythemia (ET). Patients in this international study will begin enrolling in early Spring. Bomedemstat was recently granted Fast Track Designation for the treatment of ET. Imago has two other studies of bomedemstat for MPNs planned for this year, one for the treatment of polycythemia vera and one adding bomodemstat to a regimen of ruxolitinib in patients with myelofibrosis. learn more

Jakarta Study Shows Benefits of Fedratinib -
Dr. Ruben Mesa presented his findings at ASH the findings from the JAKARTA study showing the significant health-related quality of life benefits of fedratinib which was approved by the FDA in August for the treatment of MF. learn more

Ruxolitinib Combination Shows Benefits for PV and MF Patients - According to the results released on the phase II COMBI study, ruxolitinib plus low-dose pegylated interferon-a2 (Pegasys) improved peripheral blood cell counts, bone marrow and fibrosis, and symptom burden with acceptable toxicity in patients with MF and PV. learn more
Open and Recruiting Clinical Trials
Listed below we have highlighted clinical trials for essential thrombocythemia (ET). polcythemia vera (PV), and myelofibrosis (MF). For a comprehensive list of MPN clinical trials click on each icon.
Recruiting: For patients who have previously been treated with an approved JAK inhibitor, the MOMENTUM trial is a randomized, double-blind, Phase 3 trial to evaluate the activity of momelotinib versus danazol in symptomatic, anemic subjects with myelofibrosis (MF). Go to Trial

Recruiting : This is a Phase 2 open-label, study evaluating tolerability and efficacy of navitoclax alone or when added to ruxolitinib. Go to Trial

Recruiting : This is a Phase 2 open-label study of the orally administered LSD1 inhibitor, IMG-7289, recently fast-tracked by the FDA.

Recruiting: The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.
Recruiting: This study evaluates the efficacy and safety of ruxolitinib versus anagrelide in subjects with ET who are resistant to or intolerant of hydroxyurea. Go to Trial
Would you like to participate in a clinical trial but you have questions? Click here to email us and we can help you.